LeMaitre Q2 net sales $40.7M (+64%), op income up ~128%; launches stock offering, receives CE marks

LEMAITRE VASCULAR INC

2021-Q2 EPS reported $0.68 revenue$76,553,000

Q2 preliminary net sales $40.7M (+64% reported, +35% organic vs Q2 2020).
Operating income ~$10.9-11.3M, up ~128% at midpoint vs Q2 2020.
Gross margin 65.5-66.1%, down 2.7pp at midpoint due to inventory write-downs and manufacturing inefficiencies.
Commenced underwritten public offering of common stock; proceeds to repay $23M debt and for general corporate purposes.
Received renewed CE marks for five vascular products expiring 2024; XenoSure indications narrowed (no neuro/cardiac).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.